ArticleOncogene2005
Altered expression of cell cycle genes distinguishes aggressive neuroblastoma.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.BMC cancer · 2007Pooled it
- Comprehensive Experimental and Computational Characterization of a Phenylacetamide-Based Molecule.BioMed research international · 2026Article
- From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.Journal of translational medicine · 2024Article
- Role of the CASZ1 transcription factor in tissue development and disease.European journal of medical research · 2023Review
- A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma.PloS one · 2023Article
- Inhibition of PANX1 Channels Reduces the Malignant Properties of Human High-Risk Neuroblastoma.Journal of Cancer · 2023Article
- Identification of a 5-Nutrient Stress-Sensitive Gene Signature to Predict Survival for Colorectal Cancer.BioMed research international · 2022Article
- KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma.Nature communications · 2021Article
- CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells.Molecular medicine reports · 2021Article
- The roles of the cell division cycle-associated gene family in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Article
- Co-regulation of the antagonistic RepoMan:Aurora-B pair in proliferating cells.Molecular biology of the cell · 2020Article
- CDCA2 acts as an oncogene and induces proliferation of clear cell renal cell carcinoma cells.Oncology letters · 2020Article
- The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.Journal of Cancer · 2020Article
- Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma.PloS one · 2020Article
- CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway.Frontiers in oncology · 2020Article
- CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.BMC cancer · 2019Article
- CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients.Oncotarget · 2017Article
- Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.Oncotarget · 2016Article
- Upregulation of FAM83D promotes malignant phenotypes of lung adenocarcinoma by regulating cell cycle.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
In this study, gene expression profiling was performed on 103 neuroblastoma (NB) tumors, stages 1-4 with and without MYCN amplification, using cDNA microarrays containing 42,578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.